Nursing practice questions with comprehensive rationales
NurseDive Free Nursing Practice Question
A client with chronic kidney disease has a low red blood cell count. What is the best response by the nurse?
A. Your kidneys are allowing a lot of red blood cells to leak out in your urine and causing you to become anemic
Chronic kidney disease (CKD) does not primarily cause anemia by leaking red blood cells (RBCs) into urine. While hematuria may occur in some renal conditions, anemia in CKD results mainly from reduced erythropoietin production, not RBC loss. This statement is inaccurate, as it misrepresents the primary mechanism of anemia in CKD.
B. The inflammatory process attacking your kidneys is also attacking your red blood cells
Inflammation in CKD may contribute to anemia by suppressing erythropoiesis through cytokine release, but it does not directly attack RBCs. The primary cause is erythropoietin deficiency due to impaired renal function. This statement is inaccurate, as it overstates inflammation’s role and ignores the key hormonal mechanism in CKD-related anemia.
C. The high pressure in your vessels that caused damage to your kidneys is also causing your red blood cells to burst
High vascular pressure in CKD can damage kidneys but does not directly cause RBCs to burst (hemolysis). Anemia in CKD stems from reduced erythropoietin, not mechanical RBC destruction. This statement is inaccurate, as it incorrectly links hypertension’s renal effects to direct RBC damage, misrepresenting the anemia’s cause.
D. Your kidneys are not able to synthesize the hormone responsible for stimulating red blood cell production
CKD causes anemia due to reduced erythropoietin synthesis by damaged kidneys. Erythropoietin stimulates RBC production in bone marrow. In CKD, impaired renal function decreases erythropoietin, leading to anemia. This statement is accurate, as it correctly identifies the hormonal deficiency as the primary cause of low RBC counts in CKD.
This question is an excerpt from Nurse Dive's nursing test bank - Pathophamacology Proctored Exam (Examplify). Take the full exam now
Full Explanation
Choice A reason: Chronic kidney disease (CKD) does not primarily cause anemia by leaking red blood cells (RBCs) into urine. While hematuria may occur in some renal conditions, anemia in CKD results mainly from reduced erythropoietin production, not RBC loss. This statement is inaccurate, as it misrepresents the primary mechanism of anemia in CKD.
Choice B reason: Inflammation in CKD may contribute to anemia by suppressing erythropoiesis through cytokine release, but it does not directly attack RBCs. The primary cause is erythropoietin deficiency due to impaired renal function. This statement is inaccurate, as it overstates inflammation’s role and ignores the key hormonal mechanism in CKD-related anemia.
Choice C reason: High vascular pressure in CKD can damage kidneys but does not directly cause RBCs to burst (hemolysis). Anemia in CKD stems from reduced erythropoietin, not mechanical RBC destruction. This statement is inaccurate, as it incorrectly links hypertension’s renal effects to direct RBC damage, misrepresenting the anemia’s cause.
Choice D reason: CKD causes anemia due to reduced erythropoietin synthesis by damaged kidneys. Erythropoietin stimulates RBC production in bone marrow. In CKD, impaired renal function decreases erythropoietin, leading to anemia. This statement is accurate, as it correctly identifies the hormonal deficiency as the primary cause of low RBC counts in CKD.
Similar Questions
Which patient below is at greatest risk for developing gout?
A. A 45-year-old male with a BMI of 40 taking hydrochlorothiazide and aspirin
Gout results from hyperuricemia, leading to urate crystal deposition in joints. A 45-year-old male with obesity (BMI 40) has increased purine turnover, elevating uric acid. Hydrochlorothiazide reduces urate excretion, and aspirin impairs renal uric acid clearance, significantly increasing gout risk, making this patient the most susceptible due to multiple risk factors.
B. A 39-year-old female hospitalized with bulimia that has a BMI of 24
Bulimia may cause electrolyte imbalances, but it is not strongly linked to hyperuricemia or gout. A BMI of 24 is normal, reducing obesity-related purine production. This 39-year-old female has fewer gout risk factors compared to an obese male on medications that elevate uric acid, making her less likely to develop gout.
C. A 27-year-old female with ulcerative colitis
Ulcerative colitis may cause systemic inflammation, but it is not a direct risk factor for gout. Hyperuricemia is not typically associated with inflammatory bowel diseases unless complicated by other factors like diuretic use. This 27-year-old female has a lower gout risk compared to the obese male with predisposing medications.
D. A 56-year-old male who limits consumption of smoked meat and some cheeses
Limiting purine-rich foods like smoked meat and cheeses reduces uric acid production, lowering gout risk. This 56-year-old male’s dietary habits mitigate hyperuricemia, making him the least likely to develop gout compared to the obese patient on medications that impair uric acid metabolism and excretion.
Full Explanation
Choice A reason: Gout results from hyperuricemia, leading to urate crystal deposition in joints. A 45-year-old male with obesity (BMI 40) has increased purine turnover, elevating uric acid. Hydrochlorothiazide reduces urate excretion, and aspirin impairs renal uric acid clearance, significantly increasing gout risk, making this patient the most susceptible due to multiple risk factors.
Choice B reason: Bulimia may cause electrolyte imbalances, but it is not strongly linked to hyperuricemia or gout. A BMI of 24 is normal, reducing obesity-related purine production. This 39-year-old female has fewer gout risk factors compared to an obese male on medications that elevate uric acid, making her less likely to develop gout.
Choice C reason: Ulcerative colitis may cause systemic inflammation, but it is not a direct risk factor for gout. Hyperuricemia is not typically associated with inflammatory bowel diseases unless complicated by other factors like diuretic use. This 27-year-old female has a lower gout risk compared to the obese male with predisposing medications.
Choice D reason: Limiting purine-rich foods like smoked meat and cheeses reduces uric acid production, lowering gout risk. This 56-year-old male’s dietary habits mitigate hyperuricemia, making him the least likely to develop gout compared to the obese patient on medications that impair uric acid metabolism and excretion.
What is the mechanism of action of sodium-glucose cotransporter 2 inhibitors (SGLT-2 inhibitors)?
A. Blocks glucose reabsorption by the kidneys and increases glucose excretion to lower blood sugar
SGLT-2 inhibitors, like empagliflozin, block sodium-glucose cotransporter 2 in the proximal tubule, preventing glucose reabsorption. This increases urinary glucose excretion, lowering blood sugar in type 2 diabetes. The mechanism is insulin-independent, reducing hyperglycemia and promoting weight loss, making this statement accurate for their primary action.
B. Interacts with the transcription factor that improves insulin sensitivity in the liver, skeletal muscle, and fat
SGLT-2 inhibitors do not interact with transcription factors to improve insulin sensitivity. This describes metformin’s action via AMPK activation in liver and muscle. SGLT-2 inhibitors act renally, not on transcription factors, making this statement inaccurate as it misattributes their mechanism to a different drug class.
C. Inhibits hepatic glucose production and increases insulin sensitivity in peripheral tissues
Inhibiting hepatic glucose production and increasing insulin sensitivity is metformin’s mechanism, not SGLT-2 inhibitors. SGLT-2 inhibitors work renally to excrete glucose, not by altering hepatic gluconeogenesis or peripheral insulin sensitivity. This statement is inaccurate, as it describes a different antidiabetic drug’s action.
D. Blocks ATP-sensitive K+ channels on membrane of beta cells to promote insulin secretion
Blocking ATP-sensitive K+ channels is the mechanism of sulfonylureas, like glipizide, which stimulate insulin secretion from beta cells. SGLT-2 inhibitors act on renal glucose reabsorption, not beta cell channels. This statement is inaccurate, as it incorrectly assigns a sulfonylurea mechanism to SGLT-2 inhibitors.
Full Explanation
Choice A reason: SGLT-2 inhibitors, like empagliflozin, block sodium-glucose cotransporter 2 in the proximal tubule, preventing glucose reabsorption. This increases urinary glucose excretion, lowering blood sugar in type 2 diabetes. The mechanism is insulin-independent, reducing hyperglycemia and promoting weight loss, making this statement accurate for their primary action.
Choice B reason: SGLT-2 inhibitors do not interact with transcription factors to improve insulin sensitivity. This describes metformin’s action via AMPK activation in liver and muscle. SGLT-2 inhibitors act renally, not on transcription factors, making this statement inaccurate as it misattributes their mechanism to a different drug class.
Choice C reason: Inhibiting hepatic glucose production and increasing insulin sensitivity is metformin’s mechanism, not SGLT-2 inhibitors. SGLT-2 inhibitors work renally to excrete glucose, not by altering hepatic gluconeogenesis or peripheral insulin sensitivity. This statement is inaccurate, as it describes a different antidiabetic drug’s action.
Choice D reason: Blocking ATP-sensitive K+ channels is the mechanism of sulfonylureas, like glipizide, which stimulate insulin secretion from beta cells. SGLT-2 inhibitors act on renal glucose reabsorption, not beta cell channels. This statement is inaccurate, as it incorrectly assigns a sulfonylurea mechanism to SGLT-2 inhibitors.
A client who has been diagnosed with bladder cancer is scheduled for an ileal conduit. Which statement by the nurse to the client accurately describes the ileal conduit?
A. This is always a temporary procedure that can always be reversed later
An ileal conduit is typically a permanent procedure for bladder cancer after cystectomy, as the bladder is removed. Reversibility is rare and depends on specific circumstances, not guaranteed. This statement is inaccurate, as it falsely suggests that ileal conduits are always temporary and reversible.
B. Urine is diverted into the sigmoid colon, where it is expelled through the rectum
Diverting urine to the sigmoid colon describes a ureterosigmoidostomy, not an ileal conduit. In an ileal conduit, urine is diverted through an ileal segment to an abdominal stoma, not the rectum. This statement is inaccurate, as it describes a different urinary diversion procedure.
C. Urine is diverted from the ureters to a stoma opening on the abdomen
An ileal conduit involves diverting urine from the ureters through a segment of ileum to a stoma on the abdomen, where urine is collected in an external pouch. This is the standard procedure for bladder cancer post-cystectomy, making this statement accurate and descriptive of the ileal conduit.
D. The diversion creates an opening in the bladder for urine to be eliminated
An ileal conduit does not create an opening in the bladder; the bladder is often removed in bladder cancer. Urine is diverted from the ureters to a stoma, bypassing the bladder. This statement is inaccurate, as it misrepresents the anatomical changes in an ileal conduit.
Full Explanation
Choice A reason: An ileal conduit is typically a permanent procedure for bladder cancer after cystectomy, as the bladder is removed. Reversibility is rare and depends on specific circumstances, not guaranteed. This statement is inaccurate, as it falsely suggests that ileal conduits are always temporary and reversible.
Choice B reason: Diverting urine to the sigmoid colon describes a ureterosigmoidostomy, not an ileal conduit. In an ileal conduit, urine is diverted through an ileal segment to an abdominal stoma, not the rectum. This statement is inaccurate, as it describes a different urinary diversion procedure.
Choice C reason: An ileal conduit involves diverting urine from the ureters through a segment of ileum to a stoma on the abdomen, where urine is collected in an external pouch. This is the standard procedure for bladder cancer post-cystectomy, making this statement accurate and descriptive of the ileal conduit.
Choice D reason: An ileal conduit does not create an opening in the bladder; the bladder is often removed in bladder cancer. Urine is diverted from the ureters to a stoma, bypassing the bladder. This statement is inaccurate, as it misrepresents the anatomical changes in an ileal conduit.